Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS
Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas. Our retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting Sy...
Uloženo v:
| Vydáno v: | Frontiers in pharmacology Ročník 15; s. 1454418 |
|---|---|
| Hlavní autor: | |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
Frontiers Media S.A
07.01.2025
|
| Témata: | |
| ISSN: | 1663-9812, 1663-9812 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas.
Our retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) to comprehensively evaluate Selumetinib's safety profile in real-world settings. Data from the third quarter of 2020 to the fourth quarter of 2023 were analyzed, identifying 498 adverse event reports with Selumetinib as the primary suspect drug.
Statistical analysis revealed disproportionate signals for skin and subcutaneous tissue disorders, eye disorders, and various congenital, familial, and genetic disorders. The most common adverse events were elevated blood creatine phosphokinase, rash, and acneiform dermatitis. Notably, several adverse events, including rhabdomyolysis, were identified but not listed on the Selumetinib product label, based on a comparison with the FDA drug labeling.
The study underscores the importance of early detection and management of adverse reactions associated with Selumetinib, particularly within the initial month of treatment. These findings provide valuable insights for clinicians and regulators to ensure the safe and effective use of Selumetinib in NF1 patients. |
|---|---|
| AbstractList | BackgroundNeurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas.MethodsOur retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) to comprehensively evaluate Selumetinib’s safety profile in real-world settings. Data from the third quarter of 2020 to the fourth quarter of 2023 were analyzed, identifying 498 adverse event reports with Selumetinib as the primary suspect drug.ResultsStatistical analysis revealed disproportionate signals for skin and subcutaneous tissue disorders, eye disorders, and various congenital, familial, and genetic disorders. The most common adverse events were elevated blood creatine phosphokinase, rash, and acneiform dermatitis. Notably, several adverse events, including rhabdomyolysis, were identified but not listed on the Selumetinib product label, based on a comparison with the FDA drug labeling.ConclusionThe study underscores the importance of early detection and management of adverse reactions associated with Selumetinib, particularly within the initial month of treatment. These findings provide valuable insights for clinicians and regulators to ensure the safe and effective use of Selumetinib in NF1 patients. Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas. Our retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) to comprehensively evaluate Selumetinib's safety profile in real-world settings. Data from the third quarter of 2020 to the fourth quarter of 2023 were analyzed, identifying 498 adverse event reports with Selumetinib as the primary suspect drug. Statistical analysis revealed disproportionate signals for skin and subcutaneous tissue disorders, eye disorders, and various congenital, familial, and genetic disorders. The most common adverse events were elevated blood creatine phosphokinase, rash, and acneiform dermatitis. Notably, several adverse events, including rhabdomyolysis, were identified but not listed on the Selumetinib product label, based on a comparison with the FDA drug labeling. The study underscores the importance of early detection and management of adverse reactions associated with Selumetinib, particularly within the initial month of treatment. These findings provide valuable insights for clinicians and regulators to ensure the safe and effective use of Selumetinib in NF1 patients. Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas.BackgroundNeurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas.Our retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) to comprehensively evaluate Selumetinib's safety profile in real-world settings. Data from the third quarter of 2020 to the fourth quarter of 2023 were analyzed, identifying 498 adverse event reports with Selumetinib as the primary suspect drug.MethodsOur retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) to comprehensively evaluate Selumetinib's safety profile in real-world settings. Data from the third quarter of 2020 to the fourth quarter of 2023 were analyzed, identifying 498 adverse event reports with Selumetinib as the primary suspect drug.Statistical analysis revealed disproportionate signals for skin and subcutaneous tissue disorders, eye disorders, and various congenital, familial, and genetic disorders. The most common adverse events were elevated blood creatine phosphokinase, rash, and acneiform dermatitis. Notably, several adverse events, including rhabdomyolysis, were identified but not listed on the Selumetinib product label, based on a comparison with the FDA drug labeling.ResultsStatistical analysis revealed disproportionate signals for skin and subcutaneous tissue disorders, eye disorders, and various congenital, familial, and genetic disorders. The most common adverse events were elevated blood creatine phosphokinase, rash, and acneiform dermatitis. Notably, several adverse events, including rhabdomyolysis, were identified but not listed on the Selumetinib product label, based on a comparison with the FDA drug labeling.The study underscores the importance of early detection and management of adverse reactions associated with Selumetinib, particularly within the initial month of treatment. These findings provide valuable insights for clinicians and regulators to ensure the safe and effective use of Selumetinib in NF1 patients.ConclusionThe study underscores the importance of early detection and management of adverse reactions associated with Selumetinib, particularly within the initial month of treatment. These findings provide valuable insights for clinicians and regulators to ensure the safe and effective use of Selumetinib in NF1 patients. |
| Author | Li, Lin |
| AuthorAffiliation | Department of Oncology, Zibo Municipal Hospital , Zibo , ShanDong , China |
| AuthorAffiliation_xml | – name: Department of Oncology, Zibo Municipal Hospital , Zibo , ShanDong , China |
| Author_xml | – sequence: 1 givenname: Lin surname: Li fullname: Li, Lin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39840093$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1vFCEYJqbG1to_4MFw9LIrDMwAXkxTW92kiYkfZ8LAyy7NLIwws0n_vWx3bVoPcoHwfLy8vM9rdBJTBITeUrJkTKoPftyYvGxIw5eUt5xT-QKd0a5jCyVpc_LkfIouSrkjdTGlWMdfoVOmJCdEsTPkP4cy5jSmPIUUzQTYuB3kAhh2ECdcwjqaoeDkcYFh3sIUYuhxiDjCnJMPfU5bM6USCp7uR8CrjxWsqs1UsK8Yvrm8_v7jDXrpqw1cHPdz9Ovm-ufV18Xtty-rq8vbheWdmhYOfM9Zy1zPGimU6AhpiRBt43onlG2tV0pZ33DReSV87wUI4zsgklEDzrFztDr4umTu9JjD1uR7nUzQDxcpr7WpndoBdO-sMUK6Djzl4J3yrm9Z00nLRGNbU70-HbzGud-Cs_U7shmemT5HYtjoddppSgUXTPLq8P7okNPvGcqkt6FYGAYTIc1FM9pKSpraZ6W-e1rsscrfSVVCcyDYnErJ4B8plOh9IvRDIvQ-EfqYiCqS_4hsmMx-0vXBYfif9A9eiL-1 |
| CitedBy_id | crossref_primary_10_20517_rdodj_2025_15 |
| Cites_doi | 10.1001/jamadermatol.2023.5338 10.1093/noajnl/vdad054 10.1186/s40478-024-01821-z 10.1158/1078-0432.CCR-23-0914 10.1002/pds.5624 10.1158/1078-0432.CCR-21-4205 10.1007/s40272-022-00551-w 10.1093/neuonc/noad086 10.1039/d3md00145h 10.1097/WNO.0000000000002023 10.1038/s41436-021-01170-5 10.1093/nop/npae038 10.1002/pds.677 10.1038/nrc969 10.1111/ajd.14079 10.1016/j.ctrv.2023.102675 10.1046/j.1365-2125.2003.01968.x 10.1093/jb/mvab116 10.3390/jcm13061792 10.1101/gad.1054703 10.1038/s41467-024-44755-9 10.1093/neuonc/noac109 10.1056/NEJMoa1605943 10.1007/s00415-024-12301-8 10.1093/annonc/mdg064 10.1093/neuonc/noae165.0676 10.1002/pds.1742 10.1136/bmj.o2409 10.1111/pde.15792 10.1002/ctm2.1589 10.1158/0008-5472.CAN-04-4058 10.1007/s11060-024-04617-2 10.3390/curroncol31050199 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Li. Copyright © 2025 Li. 2025 Li |
| Copyright_xml | – notice: Copyright © 2025 Li. – notice: Copyright © 2025 Li. 2025 Li |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2024.1454418 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Li |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_bdcaa78d6ef14efd9fdb53268c372c5a PMC11747384 39840093 10_3389_fphar_2024_1454418 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM ACXDI IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c469t-defb4353db328797600507752dbd79c5cf999cf2476f97fbf7e7af6e0831aedd3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001400536400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1663-9812 |
| IngestDate | Fri Oct 03 12:34:03 EDT 2025 Thu Aug 21 18:41:19 EDT 2025 Fri Sep 05 09:26:52 EDT 2025 Thu Jan 30 12:28:09 EST 2025 Tue Nov 18 20:51:05 EST 2025 Sat Nov 29 02:27:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | neurofibromatosis type I rare diseases FAERS selumetinib adverse reactions |
| Language | English |
| License | Copyright © 2025 Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c469t-defb4353db328797600507752dbd79c5cf999cf2476f97fbf7e7af6e0831aedd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Maura Massimino, Fondazione IRCCS Istituto Nazionale Tumori, Italy Reviewed by: Elisabetta Schiavello, IRCCS Istituto Nazionale dei Tumori, Italy Bartolomeo Rossi, University Hospital of Padua, Italy |
| OpenAccessLink | https://doaj.org/article/bdcaa78d6ef14efd9fdb53268c372c5a |
| PMID | 39840093 |
| PQID | 3158102976 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bdcaa78d6ef14efd9fdb53268c372c5a pubmedcentral_primary_oai_pubmedcentral_nih_gov_11747384 proquest_miscellaneous_3158102976 pubmed_primary_39840093 crossref_primary_10_3389_fphar_2024_1454418 crossref_citationtrail_10_3389_fphar_2024_1454418 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-07 |
| PublicationDateYYYYMMDD | 2025-01-07 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Wilson (B33) 2004; 57 Colombo (B7) 2022; 28 Legius (B22) 2021; 23 Suenobu (B29) 2023; 5 Trillenberg (B30) 2023; 32 Ibrahim (B18) 2024; 123 Vasudevan (B31) 2024; 15 Hummel (B17) 2024; 31 Masuzawa (B23) 2022; 171 Peacock (B26) 2024; 167 Gross (B14) 2022; 24 Guo (B15) 2024; 160 Wang (B32) 2024; 14 Borgia (B3) 2024; 13 Kassotis (B20) 2023; 44 Janinis (B19) 2003; 14 Sadighi (B28) 2024; 26 Evans (B12) 2001; 10 Needle (B24) 2024 Ram (B27) 2023; 14 Cichowski (B6) 2003; 17 Palmeiro (B25) 2023; 64 Gross (B13) 2023; 25 Azizi (B1) 2024; 11 Han (B16) 2024; 271 Küçükosmanoglu (B21) 2024; 30 Downward (B11) 2003; 3 Dhodapkar (B9) 2022; 379 Dasgupta (B8) 2005; 65 Church (B5) 2024; 12 Bate (B2) 2009; 18 Caiffa (B4) 2023; 25 Dombi (B10) 2016; 375 |
| References_xml | – volume: 160 start-page: 366 year: 2024 ident: B15 article-title: Treatment with selumetinib for café-au-lait macules and plexiform neurofibroma in pediatric patients with neurofibromatosis type 1 publication-title: JAMA dermatol. doi: 10.1001/jamadermatol.2023.5338 – volume: 5 start-page: vdad054 year: 2023 ident: B29 article-title: Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: an open-label, phase I study publication-title: Neurooncol Adv. doi: 10.1093/noajnl/vdad054 – volume: 12 start-page: 102 year: 2024 ident: B5 article-title: snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-024-01821-z – volume: 30 start-page: 1685 year: 2024 ident: B21 article-title: A real-world toxicity atlas shows that adverse events of combination therapies commonly result in additive interactions publication-title: Clin. cancer Res. doi: 10.1158/1078-0432.CCR-23-0914 – volume: 32 start-page: 910 year: 2023 ident: B30 article-title: Sensitivity and specificity in signal detection with the reporting odds ratio and the information component publication-title: Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.5624 – volume: 28 start-page: 4027 year: 2022 ident: B7 article-title: A prospective observational study of active surveillance in primary desmoid fibromatosis publication-title: Clin. cancer Res. doi: 10.1158/1078-0432.CCR-21-4205 – volume: 25 start-page: 217 year: 2023 ident: B4 article-title: Characterization of cardiac function by echocardiographic global longitudinal strain in a cohort of children with neurofibromatosis type 1 treated with selumetinib publication-title: Paediatr. drugs doi: 10.1007/s40272-022-00551-w – volume: 25 start-page: 1883 year: 2023 ident: B13 article-title: Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas publication-title: Neuro Oncol. doi: 10.1093/neuonc/noad086 – volume: 14 start-page: 1837 year: 2023 ident: B27 article-title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives publication-title: RSC Med. Chem. doi: 10.1039/d3md00145h – volume: 44 start-page: e575 year: 2023 ident: B20 article-title: Clinically aggressive low-grade optic nerve glioma in an adult treated with selumetinib publication-title: J. Neuroophthalmol. doi: 10.1097/WNO.0000000000002023 – volume: 23 start-page: 1506 year: 2021 ident: B22 article-title: Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation publication-title: Genet. Med. doi: 10.1038/s41436-021-01170-5 – volume: 11 start-page: 515 year: 2024 ident: B1 article-title: Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas publication-title: Neuro-Oncology Pract. doi: 10.1093/nop/npae038 – volume: 10 start-page: 483 year: 2001 ident: B12 article-title: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports publication-title: Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.677 – volume: 3 start-page: 11 year: 2003 ident: B11 article-title: Targeting RAS signalling pathways in cancer therapy publication-title: Nat. Rev. Cancer. doi: 10.1038/nrc969 – volume: 64 start-page: e245 year: 2023 ident: B25 article-title: MEK inhibitor-induced paronychia in a paediatric population: a tertiary centre experience publication-title: Australas. J. dermatology doi: 10.1111/ajd.14079 – volume: 123 start-page: 102675 year: 2024 ident: B18 article-title: Desmoid-type fibromatosis: current therapeutic strategies and future perspectives publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2023.102675 – volume: 57 start-page: 127 year: 2004 ident: B33 article-title: Application of data mining techniques in pharmacovigilance publication-title: Br. J. Clin. Pharmacol. doi: 10.1046/j.1365-2125.2003.01968.x – volume: 171 start-page: 109 year: 2022 ident: B23 article-title: DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway publication-title: J. Biochem. doi: 10.1093/jb/mvab116 – volume: 13 start-page: 1792 year: 2024 ident: B3 article-title: Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management publication-title: J. Clin. Med. doi: 10.3390/jcm13061792 – volume: 17 start-page: 449 year: 2003 ident: B6 article-title: Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor publication-title: Genes Dev. doi: 10.1101/gad.1054703 – volume: 15 start-page: 477 year: 2024 ident: B31 article-title: Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance publication-title: Nat. Commun. doi: 10.1038/s41467-024-44755-9 – volume: 24 start-page: 1978 year: 2022 ident: B14 article-title: Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity publication-title: Neuro Oncol. doi: 10.1093/neuonc/noac109 – volume: 375 start-page: 2550 year: 2016 ident: B10 article-title: Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1605943 – volume: 271 start-page: 2379 year: 2024 ident: B16 article-title: Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis publication-title: J. neurology doi: 10.1007/s00415-024-12301-8 – volume: 14 start-page: 181 year: 2003 ident: B19 article-title: The pharmacological treatment of aggressive fibromatosis: a systematic review publication-title: Ann. Oncol. doi: 10.1093/annonc/mdg064 – volume: 26 start-page: viii171 year: 2024 ident: B28 article-title: INNV-13. Ophthalmological complications in nf-1 patients receiving mek inhibitors: Md Anderson cancer center experience publication-title: Neuro-Oncology doi: 10.1093/neuonc/noae165.0676 – volume: 18 start-page: 427 year: 2009 ident: B2 article-title: Quantitative signal detection using spontaneous ADR reporting publication-title: Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.1742 – volume: 379 start-page: o2409 year: 2022 ident: B9 article-title: Spontaneous reporting of post-market safety signals: what evidence should support regulatory action? publication-title: BMJ Clin. Res. ed. doi: 10.1136/bmj.o2409 – year: 2024 ident: B24 article-title: Cutaneous toxicities of MEK inhibitor use in children: a comparison of binimetinib and selumetinib publication-title: Pediatr. Dermatol doi: 10.1111/pde.15792 – volume: 14 start-page: e1589 year: 2024 ident: B32 article-title: Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: the primary analysis of a phase 1 open-label study publication-title: Clin. Transl. Med. doi: 10.1002/ctm2.1589 – volume: 65 start-page: 2755 year: 2005 ident: B8 article-title: Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-4058 – volume: 167 start-page: 515 year: 2024 ident: B26 article-title: Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1 publication-title: J. neuro-oncology doi: 10.1007/s11060-024-04617-2 – volume: 31 start-page: 2644 year: 2024 ident: B17 article-title: Incidence of ophthalmological complications in NF-1 patients treated with MEK inhibitors publication-title: Curr. Oncol. Tor. Ont. doi: 10.3390/curroncol31050199 |
| SSID | ssj0000399364 |
| Score | 2.3693435 |
| Snippet | Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising... BackgroundNeurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1454418 |
| SubjectTerms | adverse reactions FAERS neurofibromatosis type I Pharmacology rare diseases selumetinib |
| Title | Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39840093 https://www.proquest.com/docview/3158102976 https://pubmed.ncbi.nlm.nih.gov/PMC11747384 https://doaj.org/article/bdcaa78d6ef14efd9fdb53268c372c5a |
| Volume | 15 |
| WOSCitedRecordID | wos001400536400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLWgYsEG8SY8KiOhbmhUEid-sCswI5CgGkGRZhf5qUaqktE4ReqGb-deJ53OIAQbNlkkjmL53tjn-HEOIa80Kx0MEzw3tSjzyuk6V0HxnKtgmKpMKHSSzP8sTk7kcqkWW1ZfuCdslAceG-7IOKu1kI77UFQ-OBWcqQFzSMtEaesEjQD1bJGp1AfjuMur8ZQMsDB1FFZnGvU_ywo6BzTekjsjURLs_xPK_H2z5NboM79L7kywkR6P1b1HbvjuPjlYjLrTl4f09PoYVTykB3RxrUh9-YCED21coR3COs38DZ5q9GGOnib9JoqbOCANaR9o9NhbDW3XGtp2NMldBqDUPSDbPraR4pwt_fQWHkbk9ZHiARU6P559_faQfJ_PTt9_zCeDhdwCKx5y54MBuMScYUCcFK7R1SiJVzrjhLK1DQAfbSgrwYMSwQThhQ7cozuZ9s6xR2Sv6zv_hFAp8JbmpVYcFeulrZwFNOOrQvkgXUaKq8Zu7KQ-jiYY5w2wEAxQkwLUYICaKUAZeb15ZzVqb_y19DuM4aYk6manG5BNzZRNzb-yKSMvrzKggf8MF0905_uL2LCilgU6ffGMPB4zYvMppoAmv1EsI3InV3bqsvuka8-SlncBjFAwWT39H7V_Rm6XaE-MM0TiOdkb1hf-BbllfwxtXO-Tm2Ip99N_AtcvP2e_AAbgHeM |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Disproportionate+adverse+event+signals+of+selumetinib+in+neurofibromatosis+type+I%3A+insights+from+FAERS&rft.jtitle=Frontiers+in+pharmacology&rft.au=Li%2C+Lin&rft.date=2025-01-07&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=15&rft_id=info:doi/10.3389%2Ffphar.2024.1454418&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fphar_2024_1454418 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |